Immunoblastic lymphoma

2010-07-01   Gian Matteo Rigolin , Francesco Cavazzini , Antonio Cuneo 

1.Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

Clinics and Pathology

Disease

Immunoblastic lymphoma is one of 3 morphologic variants of diffuse large B cell lymphoma (DLBCL). The other 2 variants are centroblastic lymphoma and anaplastic B-cell lymphoma.
The disease is not recognized as a separate entity in the WHO classification (2008).

Phenotype stem cell origin

The postulated normal counterpart is a germinal centre B cell or an activated post germinal centre B cell.

Epidemiology

It accounts for approximately 1/4 of DLBCL.

Clinics

The disease runs an aggressive course, as all DLBCL.

Pathology

The lymph node section shows an overwhelming infiltrate (>90%) by medium-to-large size cells with centrally located nucleolus and fairly abundant basophilic cytoplasm.

Treatment

Chemoimmunotherapy using anti CD20 monoclonal antibody rituximab in combination with CHOP or CHOP-like regimens is the standard of care.

Prognosis

Chemoimmunotherapy may cure 40-60% of the cases depending on age and risk factors.

Bibliography

Pubmed IDLast YearTitleAuthors
105561971999Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group.Schlegelberger B et al

Citation

Gian Matteo Rigolin ; Francesco Cavazzini ; Antonio Cuneo

Immunoblastic lymphoma

Atlas Genet Cytogenet Oncol Haematol. 2010-07-01

Online version: http://atlasgeneticsoncology.org/haematological/2092/immunoblastic-lymphoma

External Links